iRhythm Technologies to Report Fourth Quarter and Full Year 2021 Financial Results on February 23, 2022

Rhea-AI Summary

iRhythm Technologies (NASDAQ: IRTC) announced its fourth-quarter and full-year 2021 financial results will be released on February 23, 2022, after market close. The company will host a conference call at 1:30 p.m. PT / 4:30 p.m. ET to discuss the results. iRhythm specializes in cardiac care through digital health solutions, utilizing wearable biosensors and cloud-based analytics to revolutionize arrhythmia diagnosis. The company is set to highlight advancements in patient monitoring and clinical management.

Positive

• Anticipation of financial results for Q4 and FY 2021 may indicate positive performance.
• iRhythm is a leader in advancing cardiac care with innovative technology.

Negative

• None.

News Market Reaction – IRTC

-2.81%

-2.81% Session move

In the trading session that priced this news, IRTC declined 2.81%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SAN FRANCISCO, Feb. 09, 2022 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ: IRTC), a leading digital health care solutions company focused on the advancement of cardiac care, today announced that it will release financial results for the fourth quarter and full year 2021 after the close of trading on Wednesday, February 23, 2022. The company’s management team will host a corresponding conference call beginning at 1:30 p.m. PT / 4:30 p.m. ET.

Investors interested in listening to the conference call may do so by accessing the live and archived webcast of the event available on the “Investors” section of the company’s website at: www.irhythmtech.com.

About iRhythm Technologies, Inc.
iRhythm is a leading digital health care company redefining the way cardiac arrhythmias are clinically diagnosed. The company combines wearable biosensor devices worn for up to 14 days and cloud-based data analytics with powerful proprietary algorithms that distill data from millions of heartbeats into clinically actionable information. The company believes improvements in arrhythmia detection and characterization have the potential to change clinical management of patients.

Investor Relations Contact
Leigh Salvo
(415) 937-5404
investors@irhythmtech.com

Media Contact
Morgan Mathis
(310) 528-6306
irhythm@highwirepr.com

FAQ

When will iRhythm release its financial results for Q4 and full year 2021?

iRhythm will release its financial results on February 23, 2022, after market close.

What time is the iRhythm conference call scheduled on February 23, 2022?

The conference call is scheduled for 1:30 p.m. PT / 4:30 p.m. ET.

How can investors access the iRhythm conference call?

Investors can access the live and archived webcast through the 'Investors' section of iRhythm's website.

What does iRhythm specialize in?

iRhythm specializes in redefining cardiac arrhythmia diagnosis using wearable biosensors and cloud-based data analytics.